ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

FDA Approves Truvada to Prevent HIV Infection

WASHINGTON--The U.S. Food and Drug Administration Monday approved a Gilead Sciences Inc. (GILD) HIV drug for use in certain healthy people to help prevent them from contracting the virus that causes AIDS. Truvada was previously approved for use in combination with other drugs to treat HIV. The new approval will allow the drug to be used in people who are considered at high risk of becoming infected with HIV, such as those people have an HIV-infected partner. The FDA said Truvada, a pill taken daily, is to be used in combination with safe-sex practices, such as condom use, to cut the risk of sexually acquired HIV infection in adults. The agency said doctors need to test patients to make sure they are HIV-negative before prescribing Truvada as a prevention tool as well as do follow-up testing every three months. The use of Truvada alone in a person who might become infected with HIV won't treat the virus effectively. "Today's approval marks an important milestone in our fight against HIV," said FDA Commissioner Margaret A. Hamburg in a statement. "Every year, about 50,000 U.S. adults and adolescents are diagnosed with HIV infection, despite the availability of prevention methods and strategies to educate, test, and care for people living with the disease," Dr. Hamburg said.

Stock News for Gilead Sciences (GILD)
DateTimeHeadline
07/28/201520:11:00Gilead Sciences gibt Dividenden für Drittes Quartal 2015 bekannt
07/28/201520:06:00Gilead Sciences annonce son dividende du troisième trimestre...
07/28/201517:30:04Express Scripts Raises Guidance as Earnings Top Views
07/28/201517:19:14Express Scripts Raises Guidance as Earnings Top Views
07/28/201517:00:35Gilead Sales Soar on Hepatitis Drugs
07/28/201516:52:47Gilead Sales Soar on Hepatitis Drugs
07/28/201516:04:26Current Report Filing (8-k)
07/28/201516:02:00Gilead Sciences Announces Third Quarter 2015 Dividend
07/28/201516:02:00Gilead Sciences annuncia il dividendo del terzo trimestre del...
07/28/201516:01:00Gilead Sciences Announces Second Quarter 2015 Financial Results
07/28/201502:53:00Gilead annuncia alcune promozioni
07/28/201501:52:00Gilead annonce la promotion de cadres de direction
07/28/201501:45:00Gilead gibt Beförderungen im Führungspersonal bekannt
07/27/201516:30:00Gilead Announces Executive Promotions
07/24/201515:00:06FDA Approves Cholesterol Drug From Regeneron, Sanofi
07/23/201508:38:00Gilead annonce les résultats de phase 3 de la première étude vis...
07/23/201507:23:00Gilead berichtet Ergebnisse aus Phase III der ersten Studie...
07/22/201504:00:00Gilead comunica i risultati di Fase 3 derivati dal primo studio...
07/21/201517:00:00Gilead Sciences to Release Second Quarter 2015 Financial Results...
07/21/201514:06:00Gilead Announces Phase 3 Results From the First Study to Evaluate...

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad